Bank of America Lowers McKesson Price Target to $1,000

Analysts Maintain 'Buy' Rating on Pharmaceutical Distributor

Apr. 6, 2026 at 2:28pm

Got story updates? Submit your updates here. ›

Bank of America has reduced its price target for shares of McKesson (NYSE: MCK) from $1,040 to $1,000, while maintaining a 'buy' rating on the stock. The new target price still represents a potential upside of 16.23% from the company's current trading price.

Why it matters

As one of the largest pharmaceutical distributors in the United States, McKesson's financial performance and stock price are closely watched by investors. This price target adjustment by a major investment bank provides insight into Wall Street's current outlook on the company's growth prospects and valuation.

The details

In their research note, Bank of America cited the company's recent financial results and future guidance as the basis for the price target reduction. While the analysts remain bullish on McKesson's long-term potential, the new $1,000 target price reflects a more cautious near-term view compared to their previous $1,040 target.

  • Bank of America issued the updated price target on April 6, 2026.

The players

Bank of America

A major global investment bank that provides research coverage and recommendations on McKesson's stock.

McKesson Corporation

A leading pharmaceutical distribution and healthcare services company based in Irving, Texas.

Got photos? Submit your photos here. ›

What they’re saying

“We must maintain a cautious near-term outlook on McKesson, but believe the company's long-term growth potential remains strong.”

— Bank of America Analyst

What’s next

Investors will be closely watching McKesson's upcoming financial results and guidance to see if the company can meet or exceed Wall Street's expectations and potentially drive the stock price higher.

The takeaway

This price target adjustment by Bank of America reflects the ongoing challenges and uncertainty facing the pharmaceutical distribution industry, but also highlights analysts' continued confidence in McKesson's ability to navigate these headwinds and deliver long-term value for shareholders.